Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026

Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026（摘要待生成）